Literature DB >> 11371681

Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

K Jones1, P G Hoggard, S D Sales, S Khoo, R Davey, D J Back.   

Abstract

OBJECTIVES: To investigate the intracellular accumulation of HIV protease inhibitors (PI) and to assess the effect of active transport on this accumulation.
METHODS: CEM cells were incubated with a PI for 18 h and the intracellular concentration determined using cell number and radioactivity. The effect of active transport was investigated using cells expressing P-glycoprotein (CEM(VBL)) and cells expressing multidrug resistance-associated protein 1 (MRP1; CEM(E1000)). Incubations were also carried out at 4 degrees C and in the presence of 2-deoxyglucose plus rotenone to examine the effect of inhibiting active transport.
RESULTS: Nelfinavir (NFV) accumulated to the greatest extent (> 80-fold) followed by saquinavir (SQV; approximately 30-fold), ritonavir (RTV; 3-7-fold) and finally indinavir (IDV; extracellular equivalent to intracellular). In CEM(VBL) cells there was a significant reduction in the intracellular accumulation of NFV, SQV and RTV and in CEM(E1000) cells there was reduced accumulation of SQV and RTV. Inhibition of active transport processes caused a reduction in SQV and RTV accumulation but had no effect on IDV accumulation in all cell types. NFV accumulation was increased in CEM(VBL) cells as a result of inhibition of active transport.
CONCLUSIONS: Marked differences can be detected in the intracellular accumulation of HIV PI drugs in vitro. Both P-glycoprotein and MRP1 may play a role in limiting the intracellular concentration of the PI and active influx mechanisms may contribute to drug accumulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371681     DOI: 10.1097/00002030-200104130-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

3.  Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals.

Authors:  Rie Tanaka; Hideji Hanabusa; Ei Kinai; Naoki Hasegawa; Masayoshi Negishi; Shingo Kato
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 4.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

5.  Intracellular accumulation of human immunodeficiency virus protease inhibitors.

Authors:  Saye H Khoo; Patrick G Hoggard; Ian Williams; E Rhiannon Meaden; Philippa Newton; Edmund G Wilkins; Alan Smith; John F Tjia; Judy Lloyd; Kevin Jones; Nick Beeching; Peter Carey; Barry Peters; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

6.  Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Timothy J Spitzenberger; William F Elmquist; Donald W Miller
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

7.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

8.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

9.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

10.  Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

Authors:  Pranav Kumar; Robert Lodge; Nathalie Trudel; Michel Ouellet; Marc Ouellette; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.